CoreWeave and other neocloud stocks drop after Microsoft capex comes in below expectations
Shares of CoreWeave, Nebius and IREN fell as Microsoft's lower-than-expected capex figure points to infrastructure partners taking longer to deliver capacity.
Friday, 6 November 2026
News, business, world affairs and market coverage
Home / Business
Shares of CoreWeave, Nebius and IREN fell as Microsoft's lower-than-expected capex figure points to infrastructure partners taking longer to deliver capacity.
Microsoft shares rose 4% in extended trading on Wednesday after the company reported better-than-expected quarterly results, driven by 48% growth in its Azure cloud infrastructure business.
Euronext wheat prices extended losses on Tuesday to the lowest level since mid-July as market rumours of talks to halt attacks on vessels in the Black Sea eased concerns about a squeeze on Russian and Ukrainian exports.
Alphabet shares slumped more than 7% after the search giant reported a drop in free cash flow during the third quarter.
Ford Motor is set to report third-quarter results after markets close Wednesday.
August 4, 2026, 3:46 AM EDT. LIC shares dropped almost 9% after the government launched an offer for sale (OFS) of up to a 6.5% stake, setting a floor price of Rs 382, representing an 11% discount from the prior closing…
As prices have ticked up in recent years, the cost to caregivers has skyrocketed. A study, released Wednesday by AARP and shared first with NPR, finds that family caregivers — people helping out disabled, chronically il…
The Fed's benchmark affects many consumer borrowing costs, including the rates tied to mortgages, credit cards, auto loans and savings accounts.
Generac Holdings Inc. GNRC expects to generate approximately $350 million in free cash flow in 2026, even as it increases capital spending to expand production capacity and capitalize on growing demand for backup power …
Join over half a million readers using Kiplinger's insights to make smart financial decisions. Profit and prosper with our expert guidance on investing, taxes and retirement, and more. Delivered daily.
What are the best stocks to buy right now? There are thousands of publicly traded companies you can invest in. That doesn't even include the many exchange-traded funds (ETFs) and mutual funds you can buy. So it's not su…
August 5, 2026, 3:53 AM EDT.IPOs such as SpaceX and ChangXin Memory Technologies have generated worldwide interest, particularly across the tech and AI sectors. Still, with founders trying to maximize returns and invest…
The artificial intelligence (AI) frenzy remains intact as the AI infrastructure space remains rock solid, supported by an extremely bullish demand scenario. Research firm McKinsey & Co. has estimated that global AI-powe…
Shares of Stellantis were up Wednesday as the European car giant's third-quarter results showed it was making progress with its 60 billion euro turnaround plan.
Jim Cramer's top 10 things to watch in the stock market Wednesday SK Hynix blew away the numbers, and GE Vernova crushed it too. Read at source
The "Magnificent Seven" doesn't trade as a monolith anymore, challenging investors to be more discerning when picking through the market's biggest stocks rather than viewing them as a single trade.
Google has spent years pitching customers on the advantage of buying its chips, models and cloud services in one place, offering a full stack that rivals Amazon and Microsoft have tried to replicate.
The benchmark KOSPI rose 337.64 points, or 5.99%, to 5,975.98 as of 0140 GMT. If the gains hold, the index would record its biggest single-day percentage rise since July 31, as per the report.
The Federal Election Commission said Tuesday night that it identified the issue affecting its electronic filing system and was implementing a fix, after reports that a hacker or hackers had targeted the agency's systems…
Budget 2026: six charts that reveal the economic realities facing the chancellor
Elevator manufacturer Otis (NYSE:OTIS) will be reporting earnings this Wednesday before market hours. Hereâs what to expect.
British pharma company reports declining profits amid weaker vaccine sales and looming patent loss for blockbuster HIV drug
We use cookies to improve your experience and analyse site traffic. By continuing to browse, you agree to our use of cookies.